Filing Details
- Accession Number:
- 0000899243-20-009640
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-30 16:23:37
- Reporting Period:
- 2020-03-26
- Accepted Time:
- 2020-03-30 16:23:37
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1731831 | Eidos Therapeutics Inc. | EIDX | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1699848 | Franco Valle | C/O Eidos Therapeutics, Inc. 101 Montgomery Street, Suite 2000 San Francisco CA 94104 | Senior Vice President, Finance | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-03-26 | 5,000 | $7.24 | 5,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-03-26 | 3,000 | $47.87 | 2,000 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-03-26 | 2,000 | $48.85 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2020-03-26 | 5,000 | $0.00 | 5,000 | $7.24 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 41,419 | 2028-05-06 | No | 4 | M | Direct |
Footnotes
- Represents the weighted average sale price of the shares sold from $47.37 to $48.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Represents the weighted average sale price of the shares sold from $48.71 to $49.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer.
Billionaire Hedge Funds
